For the production of haemophilia and growth hormone biopharmaceuticals in Kalundborg, Denmark
An aerial view of the Kalundborg site
Danish pharmaceutical company Novo Nordisk is investing close to DKK1bn (€134m) in a new biopharmaceuticals factory in Kalundborg, Denmark.
The factory is expected to create 120–150 new jobs in Kalundborg over the next three years, the company said.
It will produce haemophilia drugs, growth hormone and other medicines.
‘We need to expand our production capacity to meet the future demand for our existing products, but also to be ready to produce future haemophilia products that are in the pipeline,’ said Per Valstorp, senior vice president, Product Supply, Novo Nordisk.
The new factory will cover formulation, freeze-drying, filling and packaging of NovoSeven haemophilia medicine, Norditropin growth hormone and the glucagon product GlucaGen.
Groundbreaking for the new factory will take place on 22 August.
‘We already have similar production in Gentofte, Denmark, and have built up great expertise in the production of biopharmaceuticals in Denmark. We were therefore never in doubt that this new factory should be placed in Denmark,’ added Valstorp.
The packaging facility is expected to be operational in 2013 and the other facilities in 2015.